Open-label, Phase 2 Clinical Trial of Crizotinib for Children and Adults with Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas Crizotinib (Xalkori®), a small molecule kinase inhibitor, ...
The drug significantly outperformed the 8 per cent who were progression free at five years in a control group taking an alternative treatment called crizotinib, with the cancer spreading after 9.1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback